@article{3d4f38ff41b448afbe0bbaf0faea5037,
title = "The Neuromodulation Appropriateness Consensus Committee on Best Practices for Dorsal Root Ganglion Stimulation",
abstract = "Introduction: The Neuromodulation Appropriateness Consensus Committee (NACC) is dedicated to improving the safety and efficacy of neuromodulation and thus improving the lives of patients undergoing neuromodulation therapies. With continued innovations in neuromodulation comes the need for evolving reviews of best practices. Dorsal root ganglion (DRG) stimulation has significantly improved the treatment of complex regional pain syndrome (CRPS), among other conditions. Through funding and organizational leadership by the International Neuromodulation Society (INS), the NACC reconvened to develop the best practices consensus document for the selection, implantation and use of DRG stimulation for the treatment of chronic pain syndromes. Methods: The NACC performed a comprehensive literature search of articles about DRG published from 1995 through June, 2017. A total of 2538 article abstracts were then reviewed, and selected articles graded for strength of evidence based on scoring criteria established by the US Preventive Services Task Force. Graded evidence was considered along with clinical experience to create the best practices consensus and recommendations. Results: The NACC achieved consensus based on peer-reviewed literature and experience to create consensus points to improve patient selection, guide surgical methods, improve post-operative care, and make recommendations for management of patients treated with DRG stimulation. Conclusion: The NACC recommendations are intended to improve patient care in the use of this evolving therapy for chronic pain. Clinicians who choose to follow these recommendations may improve outcomes.",
keywords = "chronic pain, complex regional pain syndrome, dorsal root ganglion, spinal stimulation",
author = "Deer, {Timothy R.} and Pope, {Jason E.} and Lamer, {Tim J.} and Grider, {Jay S.} and David Provenzano and Lubenow, {Timothy R.} and FitzGerald, {James J.} and Corey Hunter and Steven Falowski and Dawood Sayed and Ganesan Baranidharan and Patel, {Nikunj K.} and Timothy Davis and Alex Green and Antonio Pajuelo and Epstein, {Lawrence J.} and Michael Harned and Liong Liem and Christo, {Paul J.} and Krishnan Chakravarthy and Christopher Gilmore and Frank Huygen and Eric Lee and Pankaj Metha and Harold Nijhuis and Patterson, {Denis G.} and Erika Petersen and Pilitsis, {Julie G.} and Rowe, {Jeffery J.} and Rupert, {Matthew P.} and Ioannis Skaribas and Jennifer Sweet and Paul Verrills and Derron Wilson and Levy, {Robert M.} and Nagy Mekhail",
note = "Funding Information: This project was supported and funded by the International Neuro-modulation Society. No corporate funding was received for this project. No corporate entities had any direct input into the contents of this manuscript or the conclusions of the collaborators. Funding Information: Conflict of Interest: Dr. Deer is a consultant for Abbott, Axonics, Bioness, Flowonix, Jazz Pharm, Saluda Medical, Vertos, Spi-neThera, Nalu, and Vertiflex. Dr. Deer is a member of the advisory board for Abbott, Flowonix, Jazz Pharm, Nalu, and Vertiflex. Dr. Deer has equity options in Bioness, Vertiflex, Axonic, Vertos, SpineThera, Saluda Medical, Nalu, Cornerloc and Flowonix. He is research consultant for Abbott, Mainstay Medical, Saluda, and Vertiflex. Dr. Deer formerly had equity positions in Spinal Modulation and Nevro. Dr. Deer has a patent pending for the DRG paddle lead with Abbott. Dr. Pope has management/advisory and consulting relationships with Abbott Neuromodulation, Jazz Pharmaceuticals, Saluda Medical, Flowonix Medical Inc., VertiFlex Inc., and SPR Therapeutics. Dr. Lamer has no disclosures. Dr. Grider has no disclosures. Dr. Provenzano has consulted for Halyard Health, Boston Scientific Corp., Abbott Neuromodualtion, Bioness Inc., Nevro Corp., and Medtronic Inc. Dr. Lubenow is a consultant for Medtronic Inc., Abbott Neuromodulation, Boston Scientific Corp., Halyard Health, and Flowonix Medical Inc. Dr. FitzGerald has no disclosures. Dr. Hunter is a consultant for Abbott Neuromodulation. Dr. Falowski is a consultant and advisor for Abbott Neuromodulation. Dr. Sayed is a consultant for Abbott Neuromodulation. Dr. Baranidharan is a consultant for Abbott Neuromo-dulation, Nevro Corp., and Boston Scientific Corp. He is also an advisor for Spinal Modulation Inc., and Abbott Neuromodulation. Dr. Patel has no disclosures. Dr. Davis has no disclosures. Dr. Green is an advisor for Abbott Neuromodulation and a consultant for Renishaw. He has also received travel and accommodation fees from Abbott Neuromodulation, Boston Scientific Corp., and Medtronic Inc. Dr. Pajuelo has no disclosures. Dr. Epstein has no disclosures. Dr. Harned is a consultant for Abbott, and Medtronic Inc. Dr. Liem has no disclosures. Dr. Christo has no disclosures. Dr. Chakravarthy is a consultant for Abbott. Dr. Gilmore receives speaking fees from Abbott. Prof. Huygen is a consultant for Abbott, Medtronic Inc., and Grϋnenthal. Dr. Lee has no disclosures. Dr. Mehta has no disclosures. Dr. Nijhuis is a consultant for Saluda Medical. He also has an advisory and consulting relationship with Abbott. He has stock options with Spinal Modulation and holds a patent for an L2 DRG stimulation device. Dr. Patterson is a consultant for Abbott. Dr. Petersen is a consultant for Abbott, Medtronic Inc., and Boston Scientific Corp. Dr. Pilitsis is a shareholder and has an advisory relationship with Centauri Therapeutics and Karuna Pharmaceuticals. She receives grant support from Medtronic Inc., Boston Scientific Corp., Abbott, Nevro Corp., NIH, and Jazz Pharmaceuticals PLC. She is also a consultant for Med-tronic Inc., Boston Scientific Corp., Abbott, Jazz Pharmaceuticals PLC, Neurobridge Therapeutics Inc., and Nevro Corp. Dr. Rowe has no disclosures. Dr. Rupert is a consultant for Abbott. Dr. Skaribas has consulting relationships with Abbott and Vertiflex Inc. Dr. Sweet has no disclosures. Dr. Verrills has advisory and consulting relationships with Nevro Corp., Abbott, and Nalu Medical Inc. Dr. Wilson is a consultant for Abbott. Dr. Levy is a consultant for Abbott, Saluda Medical, Nuvectra Corp., and Nalu Medical Inc. He has stock options in Nalu Medical Inc., Bioness Inc., Vertos Medical Inc., and Nevro Corp. Dr. Mekhail has no disclosures. Funding Information: This project was supported and funded by the International Neuromodulation Society. No corporate funding was received for this project. No corporate entities had any direct input into the contents of this manuscript or the conclusions of the collaborators. Publisher Copyright: {\textcopyright} 2018 International Neuromodulation Society",
year = "2019",
month = jan,
doi = "10.1111/ner.12845",
language = "English (US)",
volume = "22",
pages = "1--35",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "1",
}